The Female Health Company / Veru Healthcare Initiates

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
39
The Female Health Company / Veru Healthcare Initiates Bioequivalence Clinical Trial Comparing Tamsulosin DRS with FLOMAX®

MIAMI, March 09, 2017 (GLOBE NEWSWIRE) -- The Female Health Company / Veru Healthcare (NASDAQ: FHCO ) today announced that it has initiated Stage 1 of a bioequivalence (BE) clinical trial designed to select the optimal formulation of its proprietary Tamsulosin Delayed Release Sachet (DRS) product. Tamsulosin DRS is a new, slow release oral powder formulation that addresses the large patient population of men with benign prostatic hyperplasia (BPH) that have difficulty swallowing tablets or capsules.

Stage 1 of the trial compares two formulations of Tamsulosin DRS to determine the optimal formulation in terms of bioequivalence to FLOMAX ® and to determine whether the formulation has a food effect. The goal is to have Stage 1 clinical trial results completed by April 2017.

Assuming successful Stage 1 data, Stage 2 of the clinical trial will test the selected formulation from Stage 1 in a larger number of subjects versus FLOMAX ® . The goal is to have Stage 2 of the clinical trial completed by late May 2017. Stability data is also being collected for the commercial manufactured drug batches to allow an anticipated NDA filing late 2017 / early 2018. The expected NDA approval would be sometime in mid to late 2018.

“The initiation of the bioequivalence clinical study represents a very important milestone in the advancement of Tamsulosin DRS, as well as in the progression of our pipeline,” said Mitchell Steiner, M.D., President and Chief Executive Officer of The Female Health Company / Veru Healthcare. “We believe the unique attributes of Tamsulosin DRS may have substantial advantages over FLOMAX ® , especially in the long-term care setting, and could improve patient compliance. Based on our pre-IND meeting in August 2016, FDA indicated that this bioequivalence trial would be acceptable means of proceeding under the 505(b)(2) regulatory pathway.”

About Tamsulosin DRS for the Treatment of BPH Overview- Tamsulosin DRS is a new powder-like formulation containing the active pharmaceutical ingredient in FLOMAX ® (tamsulosin HCI) capsules which is a commonly used medicine for the treatment of BPH, also known as enlargement of the prostate. FLOMAX ® is indicated for the treatment of BPH. Tamsulosin is a selective alpha1 blocker specific to receptors located in prostate and bladder smooth muscle. Symptoms associated with BPH occur because of increased prostate and bladder smooth muscle leading to constricted urinary flow, urinary retention, urinary infection, kidney damage and a life threatening blood infection called urosepsis. Blocking these receptors relaxes smooth muscle resulting in improved urinary flow and reduction of BPH symptoms. As stated in the FDA package insert, FLOMAX ® capsules should not be crushed, chewed or opened, because they cannot be reliably absorbed into the bloodstream. Men with high FLOMAX ® drug levels in their bloodstream are placed at risk for postural hypotension (sudden drop in blood pressure upon standing that can lead to fainting). Tablets and capsules are problematic for 15% of men over the age of 60 who have difficulty swallowing tablets and capsules and the up to 60% of men in long term facilities who have difficulty swallowing tablets and capsules because of certain medical conditions, including degenerative neurological diseases like Parkinson’s or having suffered a stroke. Not being able to take alpha1 blockers for BPH because of difficulty swallowing tablets and capsules, may lead to increased risk of acute urinary retention, urinary catheterization, urosepsis and death. Because Tamsulosin DRS is a new proprietary powder-like formulation containing the active pharmaceutical ingredient in FLOMAX ® , it would provide a more convenient and reliable way to deliver therapeutic levels of tamsulosin to men who have difficulty swallowing tablets and capsules.

Market- The initial marketing plan will target men in long term care facilities and men in the community that have difficulty swallowing tablets and capsules. Initially, a sales force is not required for this product as pharmacists and physicians have the ability to identify and to provide the appropriate formulation of tamsulosin for a patient who has BPH and difficulty swallowing tablets and capsules. Based on IMS data, FLOMAX ® and generic tamsulosin sales from March 2014 to March 2015 were $3.48 billion in the U.S. The U.S. market for all alpha blockers for BPH is estimated to be $4.5 billion annually per IMS. Men in long term care or nursing homes have up to a 60% prevalence of swallowing difficulties and account for about 13% of total tamsulosin sales, whereas over 15% of men over 60 years of age in the general population have difficulty swallowing tablets and capsules.

About The Female Health Company / Veru Healthcare The Female Health Company / Veru Healthcare is a pharmaceutical and medical device company, with a focus on the development and commercialization of pharmaceuticals that qualify for the FDA's 505(b)(2) accelerated regulatory approval pathway as well as the 505(b)(1) pathway.  The Company does business both as "Veru Healthcare" and as "The Female Health Company" and is organized as follows:

  • Veru Healthcare manages the Pharmaceuticals Division, which develops and commercializes pharmaceutical products for men's and women's health and oncology.  
  • Veru Healthcare manages the Consumer Health / Medical Devices Division, which is focused on commercializing sexual healthcare products and devices for the consumer market, including the Company's FC2 Female Condom ® in the consumer health products sector and PREBOOST ® medicated individual wipe, which is a male genital desensitizing drug product that helps in the prevention of premature ejaculation.  
  • The Female Health Company manages the Global Public Health Division, which is focused on the global public health sector FC2 business.  This division markets the Company’s Female Condom (FC2) to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world.

More information about the Female Health Company and its products can be found at www.femalehealth.com , www.veruhealthcare.com and www.femalecondom.org .  For corporate and investor-related information about the Company, please visit www.FHCinvestor.com .

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: The statements in this release which are not historical fact are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995.  Forward-looking statements in this release include statements relating to the expected timing for BE trails and an NDA filing for Tamsulosin DRS and the potential competitive advantages of Tamsulosin DRS.  These statements are based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release.  The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements.  Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following:  product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; risks relating to the ability of the Company to obtain sufficient financing on acceptable terms when needed to fund development and operations; risks related to the development of the Company's product portfolio, including clinical trials, regulatory approvals and time and cost to bring to market; many of the Company's products are at an early stage of development and the Company may fail to successfully commercialize such products; risks related to intellectual property, including licensing risks; government contracting risks, including the appropriations process and funding priorities, potential bureaucratic delays in awarding contracts, process errors, politics or other pressures, and the risk that government tenders and contracts may be subject to cancellation, delay or restructuring; a governmental tender award indicates acceptance of the bidder's price rather than an order or guarantee of the purchase of any minimum number of units, and as a result government ministries or other public sector customers may order and purchase fewer units than the full maximum tender amount; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints; risks related to the costs and other effects of litigation; the Company’s ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company’s ability to successfully integrate acquired businesses, technologies or products; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the year ended September 30, 2016.  These documents are available on the "SEC Filings" section of our website at www.veruhealthcare.com/investors .

 

Contact: Kevin Gilbert     312-366-2633

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 161

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 24

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 12

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 90

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 299

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Color Me Mine Tests Florida's Creative Leisure Demand

Updated Category News Views 72

Pottery studios are not exactly the sort of thing that makes markets pound the table, but Florida’s latest Color Me Mine push deserves a closer look. The company signed three franchise agreements in 2026 for Panama City Beach, Doral and Boca Raton, adding planned growth to a state where it already operates 11 studios. For a private franchisor, this is not a quarterly...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 58

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 109

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 56

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 51

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategic Planning for Long-Term and Short-Term Financial Success

Updated Category Investing Views 1297

Financial success rarely happens by accident. It requires deliberate planning, disciplined execution, and ongoing adjustments to align with changing circumstances. People often focus either on their short-term needs or their long-term goals, overlooking the importance of balancing them. A strong financial strategy incorporates immediate priorities while building a secure...

Continue Reading
Anticipating Caesars Entertainment's Upcoming Earnings Report

Updated Category News Views 259

A Look Ahead at Caesars Entertainment's Earnings Report Caesars Entertainment (NASDAQ: CZR) is on the verge of revealing its quarterly earnings report, drawing the interest of investors and market analysts alike. With anticipation building, here’s what the market expects before the announcement. Projected Earnings and Market Reactions Market analysts predict that...

Continue Reading
ResVita Bio's FDA Meeting Marks Progress for Netherton Syndrome

Updated Category News Views 215

ResVita Bio Advances Clinical Plans for Netherton Syndrome ResVita Bio, a biotechnology company focused on groundbreaking treatment options for skin diseases, recently shared exciting news about a pivotal meeting with the U.S. Food and Drug Administration (FDA). This engagement was crucial as it involved RVB-003, their leading investigational therapy targeted at...

Continue Reading
Solidion Technology Innovates to Advance Lithium-Sulfur Batteries

Updated Category News Views 235

Solidion Technology Makes Significant Advances in Battery Technology Solidion Technology, Inc. (NASDAQ: STI) has made remarkable progress in the field of battery technology, particularly with its lithium-sulfur (Li-S) batteries. Recently, Solidion announced a breakthrough in achieving a cell energy density of 380 Wh/kg, with future ambitions set at reaching 450 Wh/kg....

Continue Reading
Luray Peanut Co. Spices Up Snack Market with New Launch

Updated Category News Views 76

Spice Meets Peanut In An Unexpected Fusion Alright, let's shed some light on the latest concoction shaking up the snacking aisle. Luray Peanut Company has teamed up with none other than Texas Pete® to create a spicy new twist on boiled peanuts. Trust me, this is no typical snack partnership. Instead, it's the kind of daring venture that screams Southern soul with a...

Continue Reading